|
Jul 1
|
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Concerns Over Fiscal Plan, Looming Tariffs
|
|
Jul 1
|
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
|
|
Jun 30
|
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
|
|
Jun 30
|
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
|
|
Jun 18
|
Dyne at ‘attractive entry point’ following pullback, says Chardan
|
|
Jun 17
|
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
|
|
Jun 16
|
Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
|
|
Apr 21
|
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
|
|
Apr 15
|
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
|
|
Apr 14
|
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 10
|
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m
|
|
Mar 12
|
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
|
|
Mar 12
|
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating
|
|
Mar 11
|
Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
|
|
Feb 14
|
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
|
|
Feb 13
|
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)
|
|
Oct 9
|
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
|
|
Oct 7
|
Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now
|
|
Sep 23
|
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
|
|
Sep 6
|
CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares
|